COMMITTED TO HEALTHIER AGING
KLOTHO THERAPEUTICS COMPANY
KLOTHO Therapeutics (KTI) is a biotechnology company developing a patent-pending Klotho protein that has great potential to redefine society’s experience with aging.
Living Well Longer.
Klotho, a naturally occurring human protein discovered in 1997, promises to delay major diseases of aging – kidney failure, Alzheimer’s, osteoporosis, cancer, hypertension and diabetes, according to published studies. For example, National Institutes of Health report Klotho-deficient animals live 25% shorter and look older while animals overexpressing Klotho live 20-30% longer.
The company’s first focus is on kidney failure, one of the major causes of death in the U.S. that affects up to 30 million people per year, 600,000 of whom are currently on dialysis. There is no successful long-term therapy today. KTI has filed patents on modified Klotho proteins covering its expansive potential indications.
A virtual biotech.
KTI operates as a virtual business with no employees. This enables the company to refocus the 40% overhead a typical biotech spends. KTI will redeploy these resources to accelerate development and human trials, which the company is well positioned to begin in two years.
Led by successful biotech startup executives, KTI is headquartered in San Diego, California.
June 5, 2017
KLOTHO Therapeutics Named One of San Diego Venture Group’s 2017 COOL Companies
Klotho Protein Found Naturally in Humans Offers a Road Map to Longevity, Biotech Company to Create Patent-pending Klotho.